Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (6275)	11/12/1998 7:14:00 AM
From: James Baker	Read Replies (2) \| Respond to of 9523

*<<Results from the AVERT (Atorvastatin Versus Revascularization Treatments) trial demonstrated that 87 percent of patients randomised to Parke-Davis' and Pfizer's Lipitor (atorvastatin calcium), who were originally candidates for angioplasty, were able to remain instead on this medical therapy for the duration of the 18-month trial period, without experiencing any cardiovascular events. >> I was expecting a nice pop for WLA with the release of this study. The results are certainly good but not quite stat significant. It seems the WLA bulls were disappointed. Did the need for 80 mg dose cause this disappointment??? Jim